Page last updated: 2024-09-05

sorafenib and Endocrine Gland Neoplasms

sorafenib has been researched along with Endocrine Gland Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M1
Meyer, P; Missana, A1

Reviews

1 review(s) available for sorafenib and Endocrine Gland Neoplasms

ArticleYear
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
    Annales d'endocrinologie, 2013, Volume: 74 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome

2013

Other Studies

1 other study(ies) available for sorafenib and Endocrine Gland Neoplasms

ArticleYear
[Endocrinology].
    Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Benzenesulfonates; Carcinoma; Carcinoma, Medullary; Clinical Trials as Topic; Endocrine Gland Neoplasms; Endocrinology; Humans; Niacinamide; Phenylurea Compounds; Pituitary ACTH Hypersecretion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptors, Somatostatin; Somatostatin; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2012